Hyperparathyroidism. Hyperparathyroidism and other disorders of parathyroid gland
Conditions
Interventions
Intervention 1: Intervention group 1: The group receiving Cinaaclate (AMGEN pharmaceutical company of Netherland ) receives 30 mg daily. The ultimate target of this group is the PTH level between 150
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consent to participate in the study Having end-stage renal disease Patients undergoing hemodialysis
Exclusion criteria
Exclusion criteria: Parathyroid hormone less than 300 pg / ml Calcium higher than 10 mg / dl
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phosphate. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample.;Parathyroid hormone. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample.;Calcium. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Serum levels of blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaranak Sadat Filsouf
Shahre-kord University of Medical Sciences
Outcome results
None listed